U.S. markets close in 1 hour 9 minutes

AgileThought, Inc. (AGIL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1611-0.0181 (-10.10%)
As of 02:50PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close0.1792
Bid0.1657 x 1100
Ask0.1693 x 800
Day's Range0.1500 - 0.1948
52 Week Range0.1220 - 4.8000
Avg. Volume4,078,533
Market Cap8.442M
Beta (5Y Monthly)-0.09
PE Ratio (TTM)N/A
EPS (TTM)-1.6600
Earnings DateNov 10, 2023 - Nov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AGIL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AgileThought, Inc.
    Analyst Report: Silk Road Medical IncBased in Sunnyvale, California, Silk Road Medical is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR combines the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat carotid artery blockages that may cause strokes. The TCAR procedure involves threading a balloon catheter into the carotid artery from an incision near the groin to expand the narrowed artery. In parallel with the catheter procedure, another device, the ENROUTE Neuroprotection System (NPS), is used to temporarily reverse blood flow to the brain - thus preventing any broken off clots from reaching the brain and potentially causing a stroke.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    AgileThought Announces Strategic Financial Restructuring to Strengthen Financial Future

    Secures additional funding to support operations and enters into agreement to go-private with backing of its senior secured lenders, ensuring a brighter and more efficient futureIRVING, Texas, Aug. 28, 2023 (GLOBE NEWSWIRE) -- AgileThought, Inc. (“AgileThought” or the “Company”), a global provider of digital transformation services, agile software development, and next generation technology solutions, today announced additional working capital funding, a go-private transaction, and restructuring

  • GlobeNewswire

    AgileThought Reports Second Quarter 2023 Financial Results

    Continued Progress Towards Long-Term GoalsIRVING, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- AgileThought, Inc. (“AgileThought” or the “Company”) (NASDAQ: AGIL), a global provider of digital transformation services, custom software development, and next generation technologies, today reported results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights and Results: Revenue was $38.3 million, down 17.0% year over year from $46.2 million in Q2 2022 and down 8.4% sequentially fr

  • GlobeNewswire

    AgileThought Announces Resignation of Chief Financial Officer and Appointment of New CFO

    IRVING, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- AgileThought, Inc. ("AgileThought" or the “Company”) (Nasdaq: AGIL), a leading technology consulting firm, today announced that its Chief Financial Officer, Amit Singh, has resigned from his position, effective July 28, 2023, to pursue other career interests. The company thanks Amit for his valuable contributions during his tenure and wishes him the best in his future endeavors. Simultaneously, AgileThought is pleased to announce the appointment o